Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research

For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.

Novartis chemists receive “Heroes of Chemistry” honor from the American Chemical Society for work on CML drug discovery.

Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.

For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.

Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients

The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients.

There is no shortage of conversation about what AI can do. Every day brings a new headline, a new capability, a new prediction about how work will change.

Novartis R&D leaders discuss how Novartis science, technology and strategy are shaping the next decade of innovation

Radioligand therapy (RLT) has helped change what’s possible in prostate cancer treatment, but Novartis continues to work on the next wave of innovations to bring new options to patients.